Drugs / HS-10241
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06823245 | Feb → Jul 2025 overdue | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05430386 | Jan 2022 → Dec 2023 | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04477057 | Jun 2019 → Dec 2020 | cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03243643 | Aug 2017 → Jul 2019 | cancer of unknown primary site | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02977364 | Nov 2016 → Nov 2018 | carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02759640 | Sep 2016 → Mar 2018 | neoplasm | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06110663 | Dec 2023 → Dec 2024 | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05430386 ↗ |
| Action | Inhibit | “HS-10241 is a potent and selective small molecule c-Met kinase inhibitor” NCT02759640 ↗ |
| Modality | Small molecule | “potent and selective small molecule c-Met kinase inhibitor” NCT02759640 ↗ |
| Route | Oral | “HS-10241 will be administered orally once daily.” NCT02759640 ↗ |
| Target | MET | “C-met Kinase Inhibitor HS-10241” NCT02977364 ↗ |